A clinical trial of a vaccine, led by Stanford University School of Medicine researchers and designed to combat type-1 diabetes, has delivered initially promising results, suggesting that it may selectively counter the errant immune response that causes the disease. Several important findings of the multicenter, randomized, double-blind trial will be published in Science Translational Medicine...
More...
More...